Author: Doger de Spéville, Bernard; Moreno, Victor
Title: Anti-drug antibodies and drug development: challenges in the immunotherapy era. Cord-id: 68owhi1f Document date: 2021_3_10
ID: 68owhi1f
Snippet: Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel TIM3-PDL1 bispecific caused neutralizing antidrug antibodies (ADAs) in 12 out of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies.
Document: Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel TIM3-PDL1 bispecific caused neutralizing antidrug antibodies (ADAs) in 12 out of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date